A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis
收藏DataCite Commons2025-03-19 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008339/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to demonstrate the superiority of CNTO 1959 (guselkumab) to
placebo in the treatment of participants with moderate to severe plaque-type psoriasis (A
common genetically determined, chronic, inflammatory skin disease characterized by rounded
erythematous, dry, scaling patches).
提供机构：
Vivli
创建时间：
2022-08-12
